We are preparing the requested document. Please wait, this may take a while...!
|Antigen||Interleukin 1, beta (IL1B) Antibodies|
|Reactivity||Mouse (Murine) Alternatives|
|Conjugate||This IL1B antibody is un-conjugated Alternatives|
Enzyme Immunoassay (EIA), Functional Studies (Func), Western Blotting (WB)
|2 references available|
|Supplier||Log in to see|
Product Details anti-IL1B AntibodyTarget Details IL1B Application Details Handling References for anti-IL1B antibody (ABIN115865) Images
|Immunogen||Produced from sera of rabbits pre-immunized with highly pure (>98%) recombinant mIL-1-beta.|
Target Details IL1BProduct Details anti-IL1B Antibody Application Details Handling References for anti-IL1B antibody (ABIN115865) Images back to top
|Alternative Name||Interleukin-1 beta / IL-1B (IL1B Antibody Abstract)|
|Background||Interleukin 1 (IL1), originally known as lymphocyte activating factor (LAF), activates T cells and lymphocytes, which then proliferate and secrete interleukin 2. IL1 is primarily released from stimulated macrophages and monocytes, but also is released from several other cell types, and is thought to play a key role in inflammatory and immune responses. The two closely related agents, interleukin1 alpha (IL1 alpha) and interleukin1 beta (IL1 beta) bind to the same cell surface receptor, elicit nearly identical biological responses and share 25 % homology in their amino acid sequence.Synonyms: Catabolin, IL-1 beta, IL1 beta, IL1B, IL1F2|
|Pathways||NF-kappaB Signaling, Interferon-gamma Pathway, Negative Regulation of Hormone Secretion, Cellular Response to Molecule of Bacterial Origin, Carbohydrate Homeostasis, Glycosaminoglycan Metabolic Process, Myometrial Relaxation and Contraction, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Autophagy|
Application DetailsProduct Details anti-IL1B Antibody Target Details IL1B Handling References for anti-IL1B antibody (ABIN115865) Images back to top
Neutralization: To yield one-half maximal inhibition [ND50] of the biological activity ofmIL-1-beta (50 pg/mL), a concentration of 100 - 150 ng/mL of this antibody is required. Elisa: To detect mIL-1-beta by direct ELISA (using 100l/well antibody solution) aconcentration of at least 0.5g/mL of this antibody is required. This antigen affinity purifiedantibody, in conjunction with compatible secondary reagents, allows the detection of0.2-0.4 ng/well of recombinant mIL-1-beta. Western Blot: To detect mIL-1-beta by Western Blot analysis this antibody can be used at aconcentration of 0.1-0.2 μg/mL. Used in conjunction with compatible secondary reagentsthe detection limit for recombinant mIL-1-beta is 1.5-3.0 ng/lane, under either reducing ornon-reducing conditions.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user. Add. Information: Centrifuge vial prior to opening.
|Restrictions||For Research Use only|
HandlingProduct Details anti-IL1B Antibody Target Details IL1B Application Details References for anti-IL1B antibody (ABIN115865) Images back to top
|Reconstitution||Restore with sterile water to a concentration of 0.1-1.0 mg/mL.|
|Buffer||PBS, pH 7.4 without preservatives.|
|Handling Advice||Avoid repeated freezing and thawing.|
|Storage||4 °C/-20 °C|
|Storage Comment||The lyophilized antibody can be stored for one year from despatch at -20 °C. Reconstituted antibody is stable for two weeks at 2-8 °C, frozen aliquots are stable for six months at -20 °C.|
|Expiry Date||12 months|
References for anti-IL1B antibody (ABIN115865)Product Details anti-IL1B Antibody Target Details IL1B Application Details Handling Images back to top
Yao, Karabasil, Purwanti, Li, Akamatsu, Kanamori, Hosoi: "Tissue kallikrein mK13 is a candidate processing enzyme for the precursor of interleukin-1beta in the submandibular gland of mice." in: The Journal of biological chemistry, Vol. 281, Issue 12, pp. 7968-76, 2006
Gonzalez-Rey, Chorny, Robledo, Delgado: "Cortistatin, a new antiinflammatory peptide with therapeutic effect on lethal endotoxemia." in: The Journal of experimental medicine, Vol. 203, Issue 3, pp. 563-71, 2006